Pfizer Wins $10 Billion Bidding War for Metsera, Cementing Obesity as Pharma's Most Competitive Arena
Melbourne, Australia — 13 November 2025
Pfizer today completed its acquisition of Metsera for approximately US$10 billion, following a bidding war with Novo Nordisk. The deal — more than double Pfizer's original September offer — reflects fierce competition among the world's largest pharmaceutical companies to secure positions in next-generation obesity and metabolic medicine.
Metsera's portfolio centres on injectable GLP-1 and amylin combination therapies. The scale of the transaction, and the lengths Pfizer went to close it, signals just how much strategic value pharma is placing on differentiated obesity assets.
"When two of the world's largest pharmaceutical companies engage in a bidding war that reaches US$10 billion, it tells you everything about where the industry is heading," said Executive Chair Dr. Greg Collier. "Imitex sits at the intersection of the two most important trends in this space — GLP-1 combination therapy and muscle preservation — with a first-in-class mechanism that no one else is pursuing. The opportunity to create significant value for a pharma partner has never been clearer."